Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cybin Inc (CYBN.NE)

Cybin Inc (CYBN.NE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 470,092
  • Shares Outstanding, K 49,894
  • Annual Sales, $ 0 K
  • Annual Income, $ -79,055 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta -0.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.18

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.7000 +27.14%
on 12/03/25
10.0000 -2.10%
on 12/22/25
+1.8100 (+22.68%)
since 11/21/25
3-Month
7.7000 +27.14%
on 12/03/25
11.1100 -11.88%
on 10/28/25
+1.3900 (+16.55%)
since 09/22/25
52-Week
6.9500 +40.86%
on 04/09/25
15.5500 -37.04%
on 01/07/25
-4.0100 (-29.06%)
since 12/20/24

Most Recent Stories

More News
Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

- Successfully completed enrollment of 36 participants in Phase 2 study of CYB004, the Company’s deuterated dimethyltryptamine (“DMT”) program for the treatment of Generalized Anxiety Disorder (“GAD”)....

CYBN.NE : 9.7900 (-1.11%)
CYBN : 7.17 (-0.14%)
Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing...

CYBN.NE : 9.7900 (-1.11%)
CYBN : 7.17 (-0.14%)
Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

- The Phase 2 GAD study has enrolled 36 participants to evaluate the safety and efficacy of CYB004 at 12 weeks after first dose - -...

CYBN.NE : 9.7900 (-1.11%)
CYBN : 7.17 (-0.14%)
Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing...

CYBN.NE : 9.7900 (-1.11%)
CYBN : 7.17 (-0.14%)
Cybin to Participate in the Cantor Global Healthcare Conference 2025

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing...

CYBN.NE : 9.7900 (-1.11%)
CYBN : 7.17 (-0.14%)
Cybin Announces Senior Leadership Changes

Doug Drysdale to step down as Chief Executive Officer; Eric So appointed Interim Chief Executive Officer    This news release constitutes...

CYBN.NE : 9.7900 (-1.11%)
CYBN : 7.17 (-0.14%)
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

- EMBRACE, the second study within the CYB003 Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United...

CYBN.NE : 9.7900 (-1.11%)
CYBN : 7.17 (-0.14%)
Cybin Announces Results of Annual Meeting of Shareholders

Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental...

CYBN.NE : 9.7900 (-1.11%)
CYBN : 7.17 (-0.14%)
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Cybin continues to make significant progress on its journey to bring breakthrough therapies to patients by delivering on the following key milestones ...

CYBN.NE : 9.7900 (-1.11%)
CYBN : 7.17 (-0.14%)
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

- EMBRACE, the second study within the Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United States,...

CYBN.NE : 9.7900 (-1.11%)
CYBN : 7.17 (-0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential...

See More

Key Turning Points

3rd Resistance Point 10.4333
2nd Resistance Point 10.2167
1st Resistance Point 10.0033
Last Price 9.7900
1st Support Level 9.5733
2nd Support Level 9.3567
3rd Support Level 9.1433

See More

52-Week High 15.5500
Fibonacci 61.8% 12.2648
Fibonacci 50% 11.2500
Fibonacci 38.2% 10.2352
Last Price 9.7900
52-Week Low 6.9500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar